dehaze

dehaze is a German healthtech company that develops an AI platform for early detection of chronic disease risk. The company describes its product as an AI copilot that surfaces overlooked diagnoses, inappropriate treatments and future health risks. It ingests health data in heterogeneous formats — lab values, images, genomics, handwritten notes and discharge letters — and maps them onto a unified patient journey, cleansing the data through a doctor-in-the-loop process. Each patient journey is then compared against millions of other journeys, scientific research and medical guidelines to produce individual risk profiles that can be traced back to their underlying evidence.

The platform simulates potential next steps to identify likely intervention strategies, which are recommended to physicians; after clinician confirmation, AI agents follow up directly with patients to support adherence. The company positions distinct value propositions for three groups: patients (proactive risk notifications and prevention guidance), providers (AI agents that collect patient information in advance and handle follow-up), and payers (identification of overlooked diagnoses, inappropriate treatments and high-risk members for targeted intervention). dehaze states that payers can reduce healthcare spending by up to 10 percent through earlier detection. A consumer-facing application, HealthPod, provides personalized insights drawn from medical history, research and uploaded documents, and is also targeted at biopharma for indication awareness.

The company was founded on research from the University of Hamburg and grounds its work in the argument that clinicians review only a small fraction of available health data, leaving roughly a third of chronic diseases undetected at a preventable or more treatable stage. Its development, research and product teams are based in Munich.

Founding story

dehaze was founded in 2023 on research originating at the University of Hamburg, with the stated aim of identifying chronic diseases before symptoms occur. Co-founder and CEO Marius Klages previously sold VATION, a digital health coaching platform, in 2022. CTO Julian Matschinske holds a PhD in computer science from the University of Hamburg and contributed to the AIMe registry for medical AI. Co-founder Andreas Santoro is described as a serial CTO.

Business model

dehaze sells a health intelligence platform to healthcare payers (insurers) and providers, with an additional consumer-facing application, HealthPod, aimed at patients and positioned toward biopharma for indication awareness. The payer value proposition is cost reduction through earlier detection of overlooked diagnoses, inappropriate treatments and high-risk individuals; the provider proposition is time savings via AI agents that gather and follow up on patient information.

Sources describe commercial adoption by payers and providers of the platform but do not specify pricing or contract structure.

Traction

Public figures reported by the company include 251,276 health journeys analyzed, more than 250,000 patient lives analyzed, three private health networks, 300 million health events in training data and more than 200 AI algorithms. The HealthPod consumer app is reported to have logged over 150 users and more than 8,000 chats. The company says it is active worldwide with a growing number of payers using the platform.

Latest developments

In April 2026 dehaze announced a €3.2 million seed round led by YZR Capital and DN Capital, with Angel Invest, Zoho and Better Ventures participating. The proceeds are earmarked for expanding engineering, research, medical and commercial teams and for product development, including next-best-action recommendations and improved traceability. The company also recently launched HealthPod, a consumer-facing application.